Safety and Immunogenicity Study of COVID-19 Protein Subunit Recombinant Vaccine Adjuvanted With Alum+CpG 1018

NCT05228613 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

175

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

BIOLOGICAL: SARS-CoV-2 protein subunit recombinant vaccine
BIOLOGICAL: SARS-CoV-2 inactivated vaccine

Sponsor

PT Bio Farma

Collaborators

[object Object]
[object Object]